OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal

Why Outlook Therapeutics (OTLK) Is Up 57.1% After FDA Validates LYTENAVA Efficacy and BLA Resubmission

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision

Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In

OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review

Outlook Therapeutics (OTLK) Gets July 29 PDUFA Date for LYTENAVA